AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30

$6.36+0.00 (0.00%)

Close on Nov 13, 2026Market cap $159.00KP/E –Yield –

AgomAb Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

AgomAb Therapeutics's enterprise value was -$96.22M on Nov 11, 2026.

Period	Period end	Value	Change
2026	Nov 11, 2026	-$96.22M	–

See a number that looks wrong?